|
|
Дата |
|---|
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
| 03.11.2026 |
| 02.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
0.6005
|
0.65
|
0.582
|
0.551
|
0.63
|
0.629
|
|
|
102 120.11
|
557.00
|
|
0.60
|
0.70
|
0.76
|
0.495
|
0.815
|
0.6368
|
|
|
1 607 588.81
|
9 828.00
|
|
0.7345
|
0.94
|
0.79
|
0.6819
|
0.7968
|
0.7201
|
|
|
95 537.73
|
470.00
|
|
0.77
|
0.945
|
0.86
|
0.77
|
0.87
|
0.77
|
|
|
193 301.92
|
695.00
|
|
0.8244
|
0.95
|
0.85
|
0.85
|
0.9498
|
0.8829
|
|
|
64 044.30
|
661.00
|
|
0.84
|
1.12
|
0.8972
|
0.8206
|
0.9255
|
0.8448
|
|
|
77 696.52
|
757.00
|
|
0.85
|
0.9342
|
0.93
|
0.8651
|
0.9341
|
0.9003
|
|
|
70 837.90
|
1 149.00
|
|
0.8361
|
0.979
|
0.97
|
0.8801
|
0.9789
|
0.907
|
|
|
20 299.01
|
175.00
|
|
0.93
|
0.979
|
0.87
|
0.86701
|
0.95
|
0.90
|
|
|
55 664.93
|
384.00
|
|
0.87
|
0.90
|
0.905
|
0.84
|
0.92
|
0.8701
|
|
|
64 541.17
|
570.00
|
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Показать все Скрыть| 12.11.2026 |
|
| 11.08.2026 |
|
| 12.05.2026 |
|
| 31.03.2026 |
|
| 13.11.2025 |
|